Please login to the form below

Not currently logged in
Email:
Password:

GSK still interested in Human Genome Sciences

Despite having its first offer rejected the pharma company says acquiring HGS is consistent with its strategy

GlaxoSmithKline has reaffirmed its intention to pursue Human Genome Sciences (HGS), despite having its first offer for the company rejected last week, saying a deal would be aligned with its long term strategy.

Unveiling a lacklustre set of financial results for the first quarter of 2012 Sir Andrew Witty, GSK's CEO, said of the intended purchase: “This transaction is entirely consistent with our strategy to deliver sustainable growth, enhance R&D returns, simplify our business model and improve returns to shareholders.”

HGS turned down GSK's initial offer of $2.59bn, saying the bid did not reflect the "the value inherent in the company", but that it was open to alternative offers.

The two companies have been in partnership for several years, including co-developing the lupus erythematosus treatment Benlysta (belimumab) which was approved in the US in March 2011 and Europe in July 2011.

GSK will be looking to the drug to help boost performance after first quarter revenues stalled at a lower than predicted 1 per cent growth, rising to £6.64bn for the three months of 2011 as government cost-cutting measures in Europe and the US, as well as instability in the Middle East and Africa, took their toll.

Net profits dropped significantly, falling by 12 per cent from £1.58bn during the first three months of 2011 to £1.39bn for 2012, suffering by comparison with 2011's figures, which were boosted by the sale of GSK's entire shareholding in Quest Diagnostics for £584m.

HGS also released its financial results for the period, showing dramatic revenue growth, up from $26.6m for the first quarter of 2011 to $47.1m for 2012. This included $31.2m in sales achieved by Benlysta.

But the company is still losing money, although at a slower rate than last year, and reported a net loss of $93.5m for Q1 of 2012 thanks to the cost of maintaining its R&D investment.

Both GSK and HGS also published their hopes for darapladib, another drug in development as part of their existing partnership.

The therapy is currently in phase III trials that are investigating its ability to reduce the risk of adverse cardiovascular events in patients with chronic coronary heart disease.

HGS will receive 10 per cent royalties on worldwide sales if darapladib is commercialised, and has a 20 per cent co-promotion option in North America and Europe, although GSK would take full ownership if an acquisition deal can be agreed.

26th April 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics